A meta-analysis study reported in The Lancet Gastroenterology & Hepatology found liver cancer risks were similar for patients with chronic hepatitis B whether they take tenofovir or entecavir. Researchers reviewed literature from 2006 to 2020, 2018 and 2019 conference abstracts, and 31 studies that included more than 119,000 patients with chronic hepatitis B.
Liver cancer risk in HBV similar for tenofovir, entecavir
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.